nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—melanoma—lung cancer	0.638	1	CtDrD
Temozolomide—CYP3A4—Topotecan—lung cancer	0.0275	0.142	CbGbCtD
Temozolomide—CYP3A4—Gefitinib—lung cancer	0.0252	0.13	CbGbCtD
Temozolomide—CYP3A4—Teniposide—lung cancer	0.0244	0.126	CbGbCtD
Temozolomide—CYP3A4—Vinorelbine—lung cancer	0.0194	0.1	CbGbCtD
Temozolomide—CYP3A4—Crizotinib—lung cancer	0.0154	0.0796	CbGbCtD
Temozolomide—CYP3A4—Erlotinib—lung cancer	0.0149	0.0768	CbGbCtD
Temozolomide—CYP3A4—Paclitaxel—lung cancer	0.0136	0.0703	CbGbCtD
Temozolomide—CYP3A4—Irinotecan—lung cancer	0.0134	0.0694	CbGbCtD
Temozolomide—CYP3A4—Vinblastine—lung cancer	0.0119	0.0617	CbGbCtD
Temozolomide—CYP3A4—Etoposide—lung cancer	0.0108	0.0556	CbGbCtD
Temozolomide—CYP3A4—Docetaxel—lung cancer	0.00985	0.0508	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—lung cancer	0.00734	0.0379	CbGbCtD
Temozolomide—CYP3A4—Felbamate Metabolism—CYP2E1—lung cancer	0.000289	0.0907	CbGpPWpGaD
Temozolomide—CYP3A4—Codeine and Morphine Metabolism—ABCC3—lung cancer	0.000146	0.0459	CbGpPWpGaD
Temozolomide—CYP3A4—Codeine and Morphine Metabolism—UGT1A1—lung cancer	0.000137	0.0432	CbGpPWpGaD
Temozolomide—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—lung cancer	0.000129	0.0405	CbGpPWpGaD
Temozolomide—CYP3A4—Xenobiotics—CYP2A7—lung cancer	9.26e-05	0.0291	CbGpPWpGaD
Temozolomide—CYP3A4—Irinotecan Pathway—UGT1A1—lung cancer	8.78e-05	0.0276	CbGpPWpGaD
Temozolomide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—lung cancer	8.03e-05	0.0252	CbGpPWpGaD
Temozolomide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—lung cancer	8e-05	0.0251	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—GSTA1—lung cancer	7.72e-05	0.0243	CbGpPWpGaD
Temozolomide—CYP3A4—Irinotecan Pathway—ABCG2—lung cancer	7.61e-05	0.0239	CbGpPWpGaD
Temozolomide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—lung cancer	7.43e-05	0.0234	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—UGT1A1—lung cancer	7.18e-05	0.0226	CbGpPWpGaD
Temozolomide—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—lung cancer	6.43e-05	0.0202	CbGpPWpGaD
Temozolomide—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—lung cancer	6.23e-05	0.0196	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—HSD17B10—lung cancer	6.02e-05	0.0189	CbGpPWpGaD
Temozolomide—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—lung cancer	5.47e-05	0.0172	CbGpPWpGaD
Temozolomide—CYP3A4—Xenobiotics—CYP2A6—lung cancer	5.38e-05	0.0169	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP2A6—lung cancer	5.18e-05	0.0163	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—lung cancer	5.05e-05	0.0159	CbGpPWpGaD
Temozolomide—CYP3A4—Estrogen metabolism—NQO1—lung cancer	4.92e-05	0.0155	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—lung cancer	4.82e-05	0.0152	CbGpPWpGaD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—lung cancer	4.59e-05	0.0144	CbGpPWpGaD
Temozolomide—CYP3A4—Xenobiotics—CYP2E1—lung cancer	4.58e-05	0.0144	CbGpPWpGaD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—lung cancer	4.53e-05	0.0142	CbGpPWpGaD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP2E1—lung cancer	4.4e-05	0.0138	CbGpPWpGaD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—lung cancer	4.2e-05	0.0132	CbGpPWpGaD
Temozolomide—Dysuria—Doxorubicin—lung cancer	4.13e-05	0.00025	CcSEcCtD
Temozolomide—Decreased appetite—Paclitaxel—lung cancer	4.12e-05	0.000249	CcSEcCtD
Temozolomide—Dry mouth—Docetaxel—lung cancer	4.1e-05	0.000248	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Doxorubicin—lung cancer	4.1e-05	0.000248	CcSEcCtD
Temozolomide—Haemoglobin—Methotrexate—lung cancer	4.1e-05	0.000248	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Paclitaxel—lung cancer	4.1e-05	0.000248	CcSEcCtD
Temozolomide—Fatigue—Paclitaxel—lung cancer	4.09e-05	0.000247	CcSEcCtD
Temozolomide—Hepatitis—Methotrexate—lung cancer	4.08e-05	0.000247	CcSEcCtD
Temozolomide—Haemorrhage—Methotrexate—lung cancer	4.08e-05	0.000247	CcSEcCtD
Temozolomide—Pollakiuria—Doxorubicin—lung cancer	4.08e-05	0.000247	CcSEcCtD
Temozolomide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—lung cancer	4.07e-05	0.0128	CbGpPWpGaD
Temozolomide—Asthenia—Gemcitabine—lung cancer	4.07e-05	0.000246	CcSEcCtD
Temozolomide—Pain—Paclitaxel—lung cancer	4.06e-05	0.000245	CcSEcCtD
Temozolomide—Constipation—Paclitaxel—lung cancer	4.06e-05	0.000245	CcSEcCtD
Temozolomide—Confusional state—Docetaxel—lung cancer	4.05e-05	0.000245	CcSEcCtD
Temozolomide—Pharyngitis—Methotrexate—lung cancer	4.05e-05	0.000245	CcSEcCtD
Temozolomide—Urinary tract disorder—Methotrexate—lung cancer	4.03e-05	0.000244	CcSEcCtD
Temozolomide—Photosensitivity reaction—Doxorubicin—lung cancer	4.03e-05	0.000244	CcSEcCtD
Temozolomide—Oedema—Docetaxel—lung cancer	4.02e-05	0.000243	CcSEcCtD
Temozolomide—Anaphylactic shock—Docetaxel—lung cancer	4.02e-05	0.000243	CcSEcCtD
Temozolomide—Weight increased—Doxorubicin—lung cancer	4.02e-05	0.000243	CcSEcCtD
Temozolomide—Pruritus—Gemcitabine—lung cancer	4.01e-05	0.000242	CcSEcCtD
Temozolomide—Urethral disorder—Methotrexate—lung cancer	4e-05	0.000242	CcSEcCtD
Temozolomide—Infection—Docetaxel—lung cancer	4e-05	0.000242	CcSEcCtD
Temozolomide—Weight decreased—Doxorubicin—lung cancer	3.99e-05	0.000241	CcSEcCtD
Temozolomide—Feeling abnormal—Etoposide—lung cancer	3.99e-05	0.000241	CcSEcCtD
Temozolomide—Hyperglycaemia—Doxorubicin—lung cancer	3.98e-05	0.000241	CcSEcCtD
Temozolomide—Diarrhoea—Irinotecan—lung cancer	3.98e-05	0.000241	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—lung cancer	3.96e-05	0.000239	CcSEcCtD
Temozolomide—Gastrointestinal pain—Etoposide—lung cancer	3.96e-05	0.000239	CcSEcCtD
Temozolomide—Nervous system disorder—Docetaxel—lung cancer	3.94e-05	0.000239	CcSEcCtD
Temozolomide—Thrombocytopenia—Docetaxel—lung cancer	3.94e-05	0.000238	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—lung cancer	3.94e-05	0.000238	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—lung cancer	3.94e-05	0.000238	CcSEcCtD
Temozolomide—Visual impairment—Methotrexate—lung cancer	3.93e-05	0.000238	CcSEcCtD
Temozolomide—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—lung cancer	3.93e-05	0.0124	CbGpPWpGaD
Temozolomide—Feeling abnormal—Paclitaxel—lung cancer	3.91e-05	0.000236	CcSEcCtD
Temozolomide—Skin disorder—Docetaxel—lung cancer	3.91e-05	0.000236	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—lung cancer	3.9e-05	0.000236	CcSEcCtD
Temozolomide—Hypersensitivity—Cisplatin—lung cancer	3.89e-05	0.000235	CcSEcCtD
Temozolomide—Gastrointestinal pain—Paclitaxel—lung cancer	3.88e-05	0.000235	CcSEcCtD
Temozolomide—Diarrhoea—Gemcitabine—lung cancer	3.88e-05	0.000234	CcSEcCtD
Temozolomide—Erythema multiforme—Methotrexate—lung cancer	3.86e-05	0.000233	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—lung cancer	3.86e-05	0.000233	CcSEcCtD
Temozolomide—Dizziness—Irinotecan—lung cancer	3.85e-05	0.000233	CcSEcCtD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—lung cancer	3.85e-05	0.0121	CbGpPWpGaD
Temozolomide—Urticaria—Etoposide—lung cancer	3.84e-05	0.000232	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—lung cancer	3.84e-05	0.000232	CcSEcCtD
Temozolomide—Anorexia—Docetaxel—lung cancer	3.83e-05	0.000232	CcSEcCtD
Temozolomide—Body temperature increased—Etoposide—lung cancer	3.83e-05	0.000231	CcSEcCtD
Temozolomide—Abdominal pain—Etoposide—lung cancer	3.83e-05	0.000231	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—lung cancer	3.83e-05	0.000231	CcSEcCtD
Temozolomide—Eye disorder—Methotrexate—lung cancer	3.81e-05	0.000231	CcSEcCtD
Temozolomide—Tinnitus—Methotrexate—lung cancer	3.8e-05	0.00023	CcSEcCtD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—lung cancer	3.8e-05	0.0119	CbGpPWpGaD
Temozolomide—Asthenia—Cisplatin—lung cancer	3.79e-05	0.000229	CcSEcCtD
Temozolomide—Cardiac disorder—Methotrexate—lung cancer	3.79e-05	0.000229	CcSEcCtD
Temozolomide—CYP3A4—Estrogen metabolism—GSTM1—lung cancer	3.77e-05	0.0119	CbGpPWpGaD
Temozolomide—Urticaria—Paclitaxel—lung cancer	3.77e-05	0.000228	CcSEcCtD
Temozolomide—Abdominal pain—Paclitaxel—lung cancer	3.75e-05	0.000227	CcSEcCtD
Temozolomide—Body temperature increased—Paclitaxel—lung cancer	3.75e-05	0.000227	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—lung cancer	3.72e-05	0.000225	CcSEcCtD
Temozolomide—Angiopathy—Methotrexate—lung cancer	3.7e-05	0.000224	CcSEcCtD
Temozolomide—Vomiting—Irinotecan—lung cancer	3.7e-05	0.000224	CcSEcCtD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—lung cancer	3.69e-05	0.0116	CbGpPWpGaD
Temozolomide—Sinusitis—Doxorubicin—lung cancer	3.69e-05	0.000223	CcSEcCtD
Temozolomide—Immune system disorder—Methotrexate—lung cancer	3.68e-05	0.000223	CcSEcCtD
Temozolomide—Mediastinal disorder—Methotrexate—lung cancer	3.68e-05	0.000222	CcSEcCtD
Temozolomide—Rash—Irinotecan—lung cancer	3.67e-05	0.000222	CcSEcCtD
Temozolomide—Dermatitis—Irinotecan—lung cancer	3.66e-05	0.000222	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Docetaxel—lung cancer	3.66e-05	0.000222	CcSEcCtD
Temozolomide—Chills—Methotrexate—lung cancer	3.66e-05	0.000221	CcSEcCtD
Temozolomide—Headache—Irinotecan—lung cancer	3.64e-05	0.00022	CcSEcCtD
Temozolomide—Insomnia—Docetaxel—lung cancer	3.64e-05	0.00022	CcSEcCtD
Temozolomide—Diarrhoea—Cisplatin—lung cancer	3.61e-05	0.000219	CcSEcCtD
Temozolomide—Paraesthesia—Docetaxel—lung cancer	3.61e-05	0.000218	CcSEcCtD
Temozolomide—Alopecia—Methotrexate—lung cancer	3.61e-05	0.000218	CcSEcCtD
Temozolomide—Vomiting—Gemcitabine—lung cancer	3.6e-05	0.000218	CcSEcCtD
Temozolomide—Dyspnoea—Docetaxel—lung cancer	3.59e-05	0.000217	CcSEcCtD
Temozolomide—CYP3A4—Estrogen metabolism—CYP1A1—lung cancer	3.58e-05	0.0112	CbGpPWpGaD
Temozolomide—Somnolence—Docetaxel—lung cancer	3.58e-05	0.000216	CcSEcCtD
Temozolomide—Mental disorder—Methotrexate—lung cancer	3.57e-05	0.000216	CcSEcCtD
Temozolomide—Rash—Gemcitabine—lung cancer	3.57e-05	0.000216	CcSEcCtD
Temozolomide—Dermatitis—Gemcitabine—lung cancer	3.57e-05	0.000216	CcSEcCtD
Temozolomide—Hypersensitivity—Etoposide—lung cancer	3.57e-05	0.000216	CcSEcCtD
Temozolomide—Malnutrition—Methotrexate—lung cancer	3.55e-05	0.000215	CcSEcCtD
Temozolomide—Erythema—Methotrexate—lung cancer	3.55e-05	0.000215	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—lung cancer	3.55e-05	0.000215	CcSEcCtD
Temozolomide—Headache—Gemcitabine—lung cancer	3.55e-05	0.000215	CcSEcCtD
Temozolomide—Dyspepsia—Docetaxel—lung cancer	3.54e-05	0.000214	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—lung cancer	3.53e-05	0.000214	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—lung cancer	3.53e-05	0.000214	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—lung cancer	3.51e-05	0.000213	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—lung cancer	3.51e-05	0.000212	CcSEcCtD
Temozolomide—Decreased appetite—Docetaxel—lung cancer	3.5e-05	0.000211	CcSEcCtD
Temozolomide—Hypersensitivity—Paclitaxel—lung cancer	3.5e-05	0.000211	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—lung cancer	3.49e-05	0.000211	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—lung cancer	3.48e-05	0.00021	CcSEcCtD
Temozolomide—Dysgeusia—Methotrexate—lung cancer	3.48e-05	0.00021	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Docetaxel—lung cancer	3.47e-05	0.00021	CcSEcCtD
Temozolomide—Asthenia—Etoposide—lung cancer	3.47e-05	0.00021	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—lung cancer	3.47e-05	0.00021	CcSEcCtD
Temozolomide—Fatigue—Docetaxel—lung cancer	3.47e-05	0.00021	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—lung cancer	3.46e-05	0.000209	CcSEcCtD
Temozolomide—Nausea—Irinotecan—lung cancer	3.46e-05	0.000209	CcSEcCtD
Temozolomide—Constipation—Docetaxel—lung cancer	3.44e-05	0.000208	CcSEcCtD
Temozolomide—Pain—Docetaxel—lung cancer	3.44e-05	0.000208	CcSEcCtD
Temozolomide—Back pain—Methotrexate—lung cancer	3.44e-05	0.000208	CcSEcCtD
Temozolomide—CYP3A4—Irinotecan Pathway—APC—lung cancer	3.43e-05	0.0108	CbGpPWpGaD
Temozolomide—Pruritus—Etoposide—lung cancer	3.42e-05	0.000207	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—lung cancer	3.4e-05	0.000206	CcSEcCtD
Temozolomide—Asthenia—Paclitaxel—lung cancer	3.4e-05	0.000206	CcSEcCtD
Temozolomide—Nausea—Gemcitabine—lung cancer	3.37e-05	0.000204	CcSEcCtD
Temozolomide—Vomiting—Cisplatin—lung cancer	3.36e-05	0.000203	CcSEcCtD
Temozolomide—Pruritus—Paclitaxel—lung cancer	3.36e-05	0.000203	CcSEcCtD
Temozolomide—Vision blurred—Methotrexate—lung cancer	3.35e-05	0.000202	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—lung cancer	3.34e-05	0.000202	CcSEcCtD
Temozolomide—Rash—Cisplatin—lung cancer	3.33e-05	0.000201	CcSEcCtD
Temozolomide—Dermatitis—Cisplatin—lung cancer	3.33e-05	0.000201	CcSEcCtD
Temozolomide—Feeling abnormal—Docetaxel—lung cancer	3.31e-05	0.0002	CcSEcCtD
Temozolomide—Diarrhoea—Etoposide—lung cancer	3.31e-05	0.0002	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—lung cancer	3.3e-05	0.0002	CcSEcCtD
Temozolomide—Ill-defined disorder—Methotrexate—lung cancer	3.3e-05	0.000199	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—lung cancer	3.29e-05	0.000199	CcSEcCtD
Temozolomide—Gastrointestinal pain—Docetaxel—lung cancer	3.29e-05	0.000199	CcSEcCtD
Temozolomide—CYP3A4—Xenobiotics—CYP1A1—lung cancer	3.29e-05	0.0103	CbGpPWpGaD
Temozolomide—Anaemia—Methotrexate—lung cancer	3.28e-05	0.000199	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—lung cancer	3.28e-05	0.000198	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—lung cancer	3.28e-05	0.000198	CcSEcCtD
Temozolomide—Diarrhoea—Paclitaxel—lung cancer	3.25e-05	0.000196	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—lung cancer	3.21e-05	0.000194	CcSEcCtD
Temozolomide—Malaise—Methotrexate—lung cancer	3.2e-05	0.000194	CcSEcCtD
Temozolomide—Dizziness—Etoposide—lung cancer	3.2e-05	0.000194	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—lung cancer	3.19e-05	0.000193	CcSEcCtD
Temozolomide—Vertigo—Methotrexate—lung cancer	3.19e-05	0.000193	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—lung cancer	3.18e-05	0.000193	CcSEcCtD
Temozolomide—Abdominal pain—Docetaxel—lung cancer	3.18e-05	0.000192	CcSEcCtD
Temozolomide—Body temperature increased—Docetaxel—lung cancer	3.18e-05	0.000192	CcSEcCtD
Temozolomide—Leukopenia—Methotrexate—lung cancer	3.18e-05	0.000192	CcSEcCtD
Temozolomide—Chills—Doxorubicin—lung cancer	3.17e-05	0.000192	CcSEcCtD
Temozolomide—CYP3A4—Tamoxifen metabolism—CYP1A1—lung cancer	3.16e-05	0.00994	CbGpPWpGaD
Temozolomide—Dizziness—Paclitaxel—lung cancer	3.14e-05	0.00019	CcSEcCtD
Temozolomide—Nausea—Cisplatin—lung cancer	3.14e-05	0.00019	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—lung cancer	3.12e-05	0.000189	CcSEcCtD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—lung cancer	3.12e-05	0.0098	CbGpPWpGaD
Temozolomide—Cough—Methotrexate—lung cancer	3.1e-05	0.000187	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—lung cancer	3.09e-05	0.000187	CcSEcCtD
Temozolomide—Convulsion—Methotrexate—lung cancer	3.08e-05	0.000186	CcSEcCtD
Temozolomide—Vomiting—Etoposide—lung cancer	3.08e-05	0.000186	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—lung cancer	3.08e-05	0.000186	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—lung cancer	3.08e-05	0.000186	CcSEcCtD
Temozolomide—Rash—Etoposide—lung cancer	3.05e-05	0.000185	CcSEcCtD
Temozolomide—Dermatitis—Etoposide—lung cancer	3.05e-05	0.000184	CcSEcCtD
Temozolomide—Headache—Etoposide—lung cancer	3.03e-05	0.000183	CcSEcCtD
Temozolomide—Arthralgia—Methotrexate—lung cancer	3.02e-05	0.000183	CcSEcCtD
Temozolomide—Myalgia—Methotrexate—lung cancer	3.02e-05	0.000183	CcSEcCtD
Temozolomide—Vomiting—Paclitaxel—lung cancer	3.02e-05	0.000182	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—lung cancer	3.01e-05	0.000182	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3e-05	0.000182	CcSEcCtD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	2.99e-05	0.00941	CbGpPWpGaD
Temozolomide—Rash—Paclitaxel—lung cancer	2.99e-05	0.000181	CcSEcCtD
Temozolomide—Dermatitis—Paclitaxel—lung cancer	2.99e-05	0.000181	CcSEcCtD
Temozolomide—Discomfort—Methotrexate—lung cancer	2.99e-05	0.000181	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—lung cancer	2.97e-05	0.00018	CcSEcCtD
Temozolomide—Headache—Paclitaxel—lung cancer	2.97e-05	0.00018	CcSEcCtD
Temozolomide—Hypersensitivity—Docetaxel—lung cancer	2.96e-05	0.000179	CcSEcCtD
Temozolomide—Confusional state—Methotrexate—lung cancer	2.92e-05	0.000177	CcSEcCtD
Temozolomide—Anaphylactic shock—Methotrexate—lung cancer	2.9e-05	0.000175	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—lung cancer	2.9e-05	0.000175	CcSEcCtD
Temozolomide—Asthenia—Docetaxel—lung cancer	2.89e-05	0.000175	CcSEcCtD
Temozolomide—Infection—Methotrexate—lung cancer	2.88e-05	0.000174	CcSEcCtD
Temozolomide—Nausea—Etoposide—lung cancer	2.87e-05	0.000174	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—lung cancer	2.85e-05	0.000173	CcSEcCtD
Temozolomide—Pruritus—Docetaxel—lung cancer	2.85e-05	0.000172	CcSEcCtD
Temozolomide—Nervous system disorder—Methotrexate—lung cancer	2.84e-05	0.000172	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—lung cancer	2.84e-05	0.000172	CcSEcCtD
Temozolomide—Thrombocytopenia—Methotrexate—lung cancer	2.84e-05	0.000172	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—lung cancer	2.83e-05	0.000171	CcSEcCtD
Temozolomide—Nausea—Paclitaxel—lung cancer	2.82e-05	0.00017	CcSEcCtD
Temozolomide—Skin disorder—Methotrexate—lung cancer	2.82e-05	0.00017	CcSEcCtD
Temozolomide—Hyperhidrosis—Methotrexate—lung cancer	2.8e-05	0.000169	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—lung cancer	2.77e-05	0.000168	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—lung cancer	2.76e-05	0.000167	CcSEcCtD
Temozolomide—Anorexia—Methotrexate—lung cancer	2.76e-05	0.000167	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—lung cancer	2.75e-05	0.000166	CcSEcCtD
Temozolomide—Diarrhoea—Docetaxel—lung cancer	2.75e-05	0.000166	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—lung cancer	2.72e-05	0.000164	CcSEcCtD
Temozolomide—Cough—Doxorubicin—lung cancer	2.68e-05	0.000162	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—lung cancer	2.66e-05	0.000161	CcSEcCtD
Temozolomide—Dizziness—Docetaxel—lung cancer	2.66e-05	0.000161	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—lung cancer	2.65e-05	0.000161	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Methotrexate—lung cancer	2.64e-05	0.00016	CcSEcCtD
Temozolomide—Insomnia—Methotrexate—lung cancer	2.62e-05	0.000159	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—lung cancer	2.62e-05	0.000158	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—lung cancer	2.62e-05	0.000158	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—lung cancer	2.61e-05	0.000158	CcSEcCtD
Temozolomide—Paraesthesia—Methotrexate—lung cancer	2.6e-05	0.000157	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.6e-05	0.000157	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—lung cancer	2.59e-05	0.000156	CcSEcCtD
Temozolomide—Dyspnoea—Methotrexate—lung cancer	2.58e-05	0.000156	CcSEcCtD
Temozolomide—Somnolence—Methotrexate—lung cancer	2.58e-05	0.000156	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—lung cancer	2.56e-05	0.000155	CcSEcCtD
Temozolomide—Vomiting—Docetaxel—lung cancer	2.56e-05	0.000155	CcSEcCtD
Temozolomide—Dyspepsia—Methotrexate—lung cancer	2.55e-05	0.000154	CcSEcCtD
Temozolomide—Rash—Docetaxel—lung cancer	2.54e-05	0.000153	CcSEcCtD
Temozolomide—Dermatitis—Docetaxel—lung cancer	2.53e-05	0.000153	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—lung cancer	2.53e-05	0.000153	CcSEcCtD
Temozolomide—Decreased appetite—Methotrexate—lung cancer	2.52e-05	0.000152	CcSEcCtD
Temozolomide—Headache—Docetaxel—lung cancer	2.52e-05	0.000152	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—lung cancer	2.51e-05	0.000152	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—lung cancer	2.51e-05	0.000152	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Methotrexate—lung cancer	2.5e-05	0.000151	CcSEcCtD
Temozolomide—Fatigue—Methotrexate—lung cancer	2.5e-05	0.000151	CcSEcCtD
Temozolomide—Infection—Doxorubicin—lung cancer	2.49e-05	0.000151	CcSEcCtD
Temozolomide—Pain—Methotrexate—lung cancer	2.48e-05	0.00015	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—lung cancer	2.46e-05	0.000149	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—lung cancer	2.46e-05	0.000149	CcSEcCtD
Temozolomide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	2.45e-05	0.00771	CbGpPWpGaD
Temozolomide—Skin disorder—Doxorubicin—lung cancer	2.44e-05	0.000147	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—lung cancer	2.43e-05	0.000147	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—lung cancer	2.39e-05	0.000145	CcSEcCtD
Temozolomide—Nausea—Docetaxel—lung cancer	2.39e-05	0.000144	CcSEcCtD
Temozolomide—Feeling abnormal—Methotrexate—lung cancer	2.39e-05	0.000144	CcSEcCtD
Temozolomide—Gastrointestinal pain—Methotrexate—lung cancer	2.37e-05	0.000143	CcSEcCtD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP2E1—lung cancer	2.35e-05	0.00739	CbGpPWpGaD
Temozolomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	2.34e-05	0.00734	CbGpPWpGaD
Temozolomide—Urticaria—Methotrexate—lung cancer	2.3e-05	0.000139	CcSEcCtD
Temozolomide—Abdominal pain—Methotrexate—lung cancer	2.29e-05	0.000139	CcSEcCtD
Temozolomide—Body temperature increased—Methotrexate—lung cancer	2.29e-05	0.000139	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.29e-05	0.000138	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—lung cancer	2.27e-05	0.000137	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—lung cancer	2.25e-05	0.000136	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—lung cancer	2.24e-05	0.000135	CcSEcCtD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	2.23e-05	0.00702	CbGpPWpGaD
Temozolomide—Somnolence—Doxorubicin—lung cancer	2.23e-05	0.000135	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—lung cancer	2.21e-05	0.000134	CcSEcCtD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—lung cancer	2.21e-05	0.00693	CbGpPWpGaD
Temozolomide—Decreased appetite—Doxorubicin—lung cancer	2.18e-05	0.000132	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—lung cancer	2.17e-05	0.000131	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—lung cancer	2.16e-05	0.000131	CcSEcCtD
Temozolomide—Pain—Doxorubicin—lung cancer	2.15e-05	0.00013	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—lung cancer	2.15e-05	0.00013	CcSEcCtD
Temozolomide—Hypersensitivity—Methotrexate—lung cancer	2.14e-05	0.000129	CcSEcCtD
Temozolomide—Asthenia—Methotrexate—lung cancer	2.08e-05	0.000126	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—lung cancer	2.07e-05	0.000125	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—lung cancer	2.05e-05	0.000124	CcSEcCtD
Temozolomide—Pruritus—Methotrexate—lung cancer	2.05e-05	0.000124	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—lung cancer	1.99e-05	0.000121	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—lung cancer	1.98e-05	0.00012	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—lung cancer	1.98e-05	0.00012	CcSEcCtD
Temozolomide—Diarrhoea—Methotrexate—lung cancer	1.98e-05	0.00012	CcSEcCtD
Temozolomide—Dizziness—Methotrexate—lung cancer	1.92e-05	0.000116	CcSEcCtD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	1.9e-05	0.00597	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—CAT—lung cancer	1.89e-05	0.00593	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—lung cancer	1.87e-05	0.00589	CbGpPWpGaD
Temozolomide—Hypersensitivity—Doxorubicin—lung cancer	1.85e-05	0.000112	CcSEcCtD
Temozolomide—Vomiting—Methotrexate—lung cancer	1.84e-05	0.000111	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CNDP2—lung cancer	1.83e-05	0.00576	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTM2—lung cancer	1.83e-05	0.00576	CbGpPWpGaD
Temozolomide—Rash—Methotrexate—lung cancer	1.83e-05	0.000111	CcSEcCtD
Temozolomide—Dermatitis—Methotrexate—lung cancer	1.83e-05	0.00011	CcSEcCtD
Temozolomide—Headache—Methotrexate—lung cancer	1.82e-05	0.00011	CcSEcCtD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	1.81e-05	0.00569	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTM2—lung cancer	1.81e-05	0.00568	CbGpPWpGaD
Temozolomide—Asthenia—Doxorubicin—lung cancer	1.8e-05	0.000109	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—lung cancer	1.78e-05	0.000107	CcSEcCtD
Temozolomide—Nausea—Methotrexate—lung cancer	1.72e-05	0.000104	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—lung cancer	1.72e-05	0.000104	CcSEcCtD
Temozolomide—CYP3A4—Tryptophan metabolism—CYP1A1—lung cancer	1.69e-05	0.00531	CbGpPWpGaD
Temozolomide—Dizziness—Doxorubicin—lung cancer	1.66e-05	0.0001	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—CYP2A7—lung cancer	1.66e-05	0.00521	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP2A7—lung cancer	1.63e-05	0.00514	CbGpPWpGaD
Temozolomide—Vomiting—Doxorubicin—lung cancer	1.6e-05	9.65e-05	CcSEcCtD
Temozolomide—Rash—Doxorubicin—lung cancer	1.58e-05	9.57e-05	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—lung cancer	1.58e-05	9.56e-05	CcSEcCtD
Temozolomide—Headache—Doxorubicin—lung cancer	1.57e-05	9.51e-05	CcSEcCtD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	1.54e-05	0.00484	CbGpPWpGaD
Temozolomide—Nausea—Doxorubicin—lung cancer	1.49e-05	9.02e-05	CcSEcCtD
Temozolomide—CYP3A4—Biological oxidations—GSTA3—lung cancer	1.48e-05	0.00464	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTA3—lung cancer	1.46e-05	0.00458	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	1.36e-05	0.00429	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTA4—lung cancer	1.35e-05	0.00424	CbGpPWpGaD
Temozolomide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—lung cancer	1.35e-05	0.00423	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTA4—lung cancer	1.33e-05	0.00419	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTA2—lung cancer	1.32e-05	0.00414	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTA1—lung cancer	1.27e-05	0.00399	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—AKR1C1—lung cancer	1.2e-05	0.00377	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—UGT1A1—lung cancer	1.18e-05	0.00371	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—UGT1A1—lung cancer	1.16e-05	0.00366	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	1.11e-05	0.00348	CbGpPWpGaD
Temozolomide—CYP3A4—Tryptophan metabolism—MDM2—lung cancer	1.04e-05	0.00327	CbGpPWpGaD
Temozolomide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	1.02e-05	0.0032	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—HPGDS—lung cancer	1e-05	0.00315	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTT1—lung cancer	9.73e-06	0.00306	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP2A6—lung cancer	9.62e-06	0.00302	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GCLC—lung cancer	9.62e-06	0.00302	CbGpPWpGaD
Temozolomide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—lung cancer	8.25e-06	0.00259	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP2E1—lung cancer	8.18e-06	0.00257	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP2E1—lung cancer	8.07e-06	0.00254	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTP1—lung cancer	6.75e-06	0.00212	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	6.65e-06	0.00209	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—GSTM1—lung cancer	6.2e-06	0.00195	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	6.12e-06	0.00192	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—CYP1A1—lung cancer	5.88e-06	0.00185	CbGpPWpGaD
Temozolomide—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	5.8e-06	0.00182	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—COL4A3BP—lung cancer	5.17e-06	0.00163	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—AZIN2—lung cancer	5.17e-06	0.00163	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ATP5H—lung cancer	4.4e-06	0.00138	CbGpPWpGaD
Temozolomide—CYP3A4—Biological oxidations—POMC—lung cancer	4.38e-06	0.00138	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PLBD1—lung cancer	3.92e-06	0.00123	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HSD17B10—lung cancer	3.58e-06	0.00113	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CKB—lung cancer	3.33e-06	0.00105	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTM2—lung cancer	3.13e-06	0.000985	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CNDP2—lung cancer	3.13e-06	0.000985	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—MTMR3—lung cancer	3.05e-06	0.000958	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PGAM1—lung cancer	2.97e-06	0.000933	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP2A7—lung cancer	2.83e-06	0.00089	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—SDC4—lung cancer	2.77e-06	0.000871	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA3—lung cancer	2.53e-06	0.000794	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—RRM1—lung cancer	2.53e-06	0.000794	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—B4GALT5—lung cancer	2.37e-06	0.000746	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA4—lung cancer	2.31e-06	0.000726	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA2—lung cancer	2.25e-06	0.000707	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTA1—lung cancer	2.17e-06	0.000682	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ABCC3—lung cancer	2.15e-06	0.000675	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—AKR1C1—lung cancer	2.08e-06	0.000654	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—UGT1A1—lung cancer	2.02e-06	0.000634	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GNG11—lung cancer	1.95e-06	0.000612	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ALDOA—lung cancer	1.85e-06	0.000582	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NCOA3—lung cancer	1.8e-06	0.000565	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ADCY1—lung cancer	1.75e-06	0.00055	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ABCG2—lung cancer	1.75e-06	0.00055	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—HPGDS—lung cancer	1.72e-06	0.000539	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ENO2—lung cancer	1.72e-06	0.000539	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.71e-06	0.000536	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTT1—lung cancer	1.66e-06	0.000523	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GCLC—lung cancer	1.65e-06	0.000517	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP2A6—lung cancer	1.65e-06	0.000517	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ENO1—lung cancer	1.56e-06	0.00049	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP2E1—lung cancer	1.4e-06	0.00044	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—NQO1—lung cancer	1.38e-06	0.000435	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—STK11—lung cancer	1.25e-06	0.000392	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTP1—lung cancer	1.15e-06	0.000363	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CAT—lung cancer	1.12e-06	0.000353	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ABCB1—lung cancer	1.09e-06	0.000343	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—TYMS—lung cancer	1.07e-06	0.000337	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—GSTM1—lung cancer	1.06e-06	0.000333	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CYP1A1—lung cancer	1.01e-06	0.000316	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ERCC2—lung cancer	9.97e-07	0.000313	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—APOA1—lung cancer	8.62e-07	0.000271	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CG—lung cancer	7.87e-07	0.000247	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—POMC—lung cancer	7.49e-07	0.000236	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—CREBBP—lung cancer	7.3e-07	0.000229	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CD—lung cancer	6.92e-07	0.000218	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—ALB—lung cancer	6.83e-07	0.000215	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CB—lung cancer	6.03e-07	0.00019	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PTGS2—lung cancer	5.98e-07	0.000188	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PTEN—lung cancer	5.21e-07	0.000164	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—EP300—lung cancer	4.97e-07	0.000156	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—PIK3CA—lung cancer	3.68e-07	0.000116	CbGpPWpGaD
Temozolomide—CYP3A4—Metabolism—AKT1—lung cancer	3e-07	9.44e-05	CbGpPWpGaD
